Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Gains from Investment Securities: 2021-2025

Historic Gains from Investment Securities for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $10.0 million.

  • Janux Therapeutics' Gains from Investment Securities rose 3.81% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 3.81%. This contributed to the annual value of $8.9 million for FY2024, which is 11.06% up from last year.
  • As of Q3 2025, Janux Therapeutics' Gains from Investment Securities stood at $10.0 million, which was up 110,711.10% from -$9,000 recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' Gains from Investment Securities peaked at $23.5 million during Q4 2024, and registered a low of -$1.3 million during Q1 2022.
  • Over the past 3 years, Janux Therapeutics' median Gains from Investment Securities value was $9.1 million (recorded in 2023), while the average stood at $7.3 million.
  • Examining YoY changes over the last 5 years, Janux Therapeutics' Gains from Investment Securities showed a top increase of 108,351.00% in 2022 and a maximum decrease of 2,100.00% in 2022.
  • Over the past 5 years, Janux Therapeutics' Gains from Investment Securities (Quarterly) stood at $7,000 in 2021, then soared by 108,351.00% to $344,000 in 2022, then declined by 12.79% to $300,000 in 2023, then skyrocketed by 7,733.33% to $23.5 million in 2024, then rose by 3.81% to $10.0 million in 2025.
  • Its Gains from Investment Securities was $10.0 million in Q3 2025, compared to -$9,000 in Q2 2025 and $10.0 million in Q1 2025.